Chula ARi Pilots Model Communities to Address Thailand’s Aging Boom
BANGKOK, Sept. 29, 2025 /PRNewswire/ -- Chula ARi, an interdisciplinary initiative by Chulalongkorn University, addresses the challenges of Thailand's rapidly aging society by using research to develop comprehensive elderly care models across economic, social, health, environmental, and innovation dimensions. The project also encourages pre-senior citizens to prepare for future aging challenges. Chula ARi Pilots Model...
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 in Boston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovative solutions at Booth #210, engaging with researchers to support their cell and gene therapy projects. Engagement and Feedback...
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights Zevorcabtagene autoleucel (CT053) NDA was approved by the NMPA. Satricabtagene autoleucel (CT041)...
Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors
- The first EpCAM targeted CAR-T product obtained US/CN IND approval. - Acceptable safety profiles and preliminary efficacy were observed in Investigator-Initiated Trial (IIT) clinical studies of IMC001. SHANGHAI, Feb. 23, 2024 /PRNewswire/ -- Immunofoco, a company dedicated to developing cell therapy products for solid tumors, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application...
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College...
78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in treating postmenopausal women with osteoporosis (PMO) Data from the Phase III RCT showed...
Singleron Acquires Proteona
NANJING/SUZHOU, China and COLOGNE, Germany and SINGAPORE, March 7, 2022 /PRNewswire/ -- Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisition of Proteona Pte. Ltd., a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe. By acquiring...
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR)...
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA’S FIRST MEDICAL TOURISM YEAR
KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." ...
MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI
ISLAMABAD, Aug. 13, 2025 /PRNewswire/ --In a pioneering step towards elevating nursing education in Pakistan, MindHYVE.ai has signed strategic Memorandum of Understanding (MoU) with the Institute of Contemporary Studies (ICS) and the National Excellence Institute (NEI). MindHYVE.ai, ICS, and NEI Forge Partnership to Revolutionize Nursing Education in Pakistan with...
Farmmi Healthcare Subsidiary Receives BRC and HACCP Certifications
LISHUI, China, Oct. 18, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI) announced that one of its healthcare subsidiaries, Zhejiang Farmmi Biotechnology Co., Ltd., has been assessed and has been awarded the certificate for compliance with the requirements of BRC Global Standard Food Safety Issue 8: February 2019 ,...
